TrialThe Lancet. Respiratory medicine2022

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.

Ruvim Izikson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.